MRAI Marpai, Inc. Insider Trading

Director Robert M Pons bought 50,000 shares at $1.00; stock down 27.4% from 52-week high amid unprofitable fundamentals

Robert M Pons, a director at Marpai, Inc., purchased 50,000 shares at $1.00 on 2025-11-07, increasing his holdings by 50,000 shares to 359,200 shares total. This buy occurs as the stock trades at $1.19, down 27.4% from its 52-week high and down 9.8% over the prior 30 days. The company's fundamentals are strained: latest quarterly revenue was $4.0M against a net loss of $3.5M, with annual revenue declining 24.2% year-over-year. Pons' prior four purchases at this same ticker show mixed timing outcomes—two were well-timed at the 90-day mark, but two resulted in significant declines (61.0% and 42.0% losses at 30 days). A cluster pattern is present with two other insiders also buying within the past 14 days, though his cross-ticker track record shows an average 90-day return of +13.2% against a 50% win rate.

Director Eitan Yaron buys 100,000 shares of MRAI at $1.00; stock down -27.4% from 52-week high amid -24.2% annual revenue decline.

Director Eitan Yaron purchased 100,000 shares at $1.00 on 2025-11-07, increasing his holdings by 10.1% to 1,089,073 shares post-transaction. The purchase occurs against a deteriorating stock backdrop: MRAI is trading -27.4% from its 52-week high and -9.8% over the last 30 days, while fundamentals show annual revenue declining -24.2% and the company posting a full-year net loss of $-3,494,000.00. His prior five buys at MRAI show mixed timing: two achieved positive 90-day returns (including a +122.8% gain following a January 2024 purchase), but three resulted in 90-day losses of -20.4%, -24.8%, and -46.7%, suggesting inconsistent execution. The filing also reflects a cluster pattern with 2 other insiders buying within the past 14 days, which may indicate coordinated confidence or response to external circumstances rather than isolated conviction.

Director Shiv Sagiv bought 50,000 shares of MRAI at $1.00 on 2025-11-07; part of 2-insider cluster buy pattern.

Director Shiv Sagiv purchased 50,000 shares at $1.00, increasing his holdings by 22.5% to 272,000 shares. This buy occurs within a cluster pattern: 2 other insiders purchased MRAI shares within the past 14 days, suggesting coordinated conviction at current price levels. The transaction occurs when the stock trades at $1.19, down 27.4% from its 52-week high and down 15.0% over the past 90 days, following a period of weakness. However, the underlying business fundamentals remain challenged: the company posted a net loss of $-3,494,000.00 in the latest quarter on revenue of $4,037,000.00, and annual revenue contracted 24.2% year-over-year. The multi-insider buy pattern paired against ongoing operational losses and revenue decline creates a tension that warrants scrutiny of insider motivation relative to business trajectory.

CEO Damien Lamendola buys 147,058 shares of MRAI at $1.36 (Sept 30), expanding stake to 6.42M shares as company faces -24.2% revenue decline and $4.4M net loss.

Lamendola purchased 147,058 shares for $200.0K at $1.36 on 2025-09-30, expanding his holdings to 6.42M shares. This marks his third buy in 21 days at MRAI, following purchases on 2025-09-10 and 2025-07-29. At the company level, fundamentals show stress: latest quarterly revenue of $4.7M represents -24.2% annual revenue growth, and the company recorded a net loss of $4.4M over its most recent full fiscal year. The stock currently trades at $1.44, +4.4% over 30 days but -12.2% from its 52-week high. Among his prior trades at this ticker, timing has been mixed (1 of 2 measurable 90-day outcomes well-timed, including a +199.4% return on his 2024-08-28 buy), but recent prior-trade outcomes at this specific ticker show outsized 30-day gains (+28.2%, +25.0% on the July purchases). The rapid accumulation cadence and positive interim price movement on recent purchases merit monitoring against the backdrop of deteriorating company-level revenue and profitability metrics.

CEO Lamendola buys 896.9K MRAI shares for $950.0K at $1.06 amid -20.0% 30-day decline; mixed timing record on this ticker.

Lamendola purchased 896,903 shares at $1.06, raising his holdings to 6,272,835 shares (+16.7% vs prior holdings). The purchase occurs while MRAI shares have declined 20.0% over the past 30 days and sit 32.9% below the 52-week high of $1.64, presenting a lower entry point relative to recent performance. Examining his same-ticker history at MRAI: two recent buys on 2025-07-29 and 2025-07-17 posted gains of 28.2% and 25.0% over 30 days respectively, but earlier trades at this ticker showed mixed outcomes (one 90-day win of 199.4%, offset by 90-day losses of -75.9% and -44.8%), with only 1 of 3 prior buys well-timed at the 90-day mark. Fundamentals remain challenged: the company reported negative net income of -4.4M on quarterly revenue of 4.7M, with full-year revenue declining 24.2% year-over-year and an 18.0M market cap, suggesting structural headwinds that may weigh on near-term outcomes despite recent intra-quarter momentum.

MRAI CEO Lamendola buys 371,470 shares at $1.08 on 2025-07-29; 12 days after prior buy at same price.

Damien Lamendola, Chief Executive Officer of Marpai, Inc., purchased 371,470 shares at $1.08 on 2025-07-29, investing $399,998.90 to increase his holdings from 5,004,462 to 5,375,932 shares (+7.4%). This buy occurred just 12 days after his previous purchase on 2025-07-17 at the same price level ($1.08). The current price of $1.19 sits -27.4% below the 52-week high and has declined -13.8% over the past 30 days, despite a +13.3% gain over 90 days. Notably, Marpai reported negative net income of $-3,069,000.00 in its latest quarter and -24.2% annual revenue decline, with a market cap of only $17,727,056.34. His prior trades at MRAI show mixed results: 2 of 4 measurable same-ticker buys exhibited positive 90-day returns (those on 2024-08-28 returning +199.4% and 2024-01-16 returning +122.8%), while the others turned negative. The consecutive purchases at identical prices, combined with the company's unprofitable fundamentals and recent price weakness, warrant investor scrutiny of whether the CEO perceives value or is meeting predetermined accumulation targets.

CEO Damien Lamendola purchases 86,805 shares of MRAI at $1.15 for $99,999.36; holdings rise to 5,004,462 shares as stock trades 18.3% below 52-week high

Damien Lamendola, as Chief Executive Officer, purchased 86,805 shares at $1.15 on 2025-07-17, bringing his total holdings to 5,004,462 shares. The transaction occurred at a price 14.2% below the current market price of $1.34 and represents accumulation within a 52-week range of $0.43–$1.64, currently 18.3% from the high. His prior trading activity at MRAI shows mixed timing outcomes: 3 of 5 prior buys were well-timed at the 90-day mark, though the most recent buy on 2024-08-28 achieved +20.6% 30-day and +199.4% 90-day returns while the 2024-05-10 purchase resulted in -66.7% 30-day and -75.9% 90-day returns. The underlying company reported net income of $-3.1M against $5.4M revenue in the latest quarter, with annual revenue declining 24.2% year-over-year; the company remains unprofitable on a full-year basis. The CEO's willingness to deploy capital at $1.15 into a loss-making business with contracting revenues occurs alongside a recent 90-day appreciation of +39.6%, which may signal either conviction in a turnaround or a discretionary allocation decision in a volatile micro-cap environment.

Director Eitan Yaron buys 110.6K MRAI shares at $1.13; stakes cluster buy, follows 52-week recovery +63.1% (30d), +112.4% (90d)

Eitan Yaron purchased 110,619 shares at $1.13 on 2024-12-05, increasing his holdings by 16.3% to 789,073 shares total. This purchase occurs alongside 2 other insider buys within the past 14 days, forming a cluster pattern. The timing coincides with significant recent price momentum—the stock has rallied +63.1% over 30 days and +112.4% over 90 days from near its 52-week low of $0.43, though it remains -54.8% below its 52-week high of $2.81. At the same ticker, Yaron's prior 4 purchases show mixed outcomes: 2 were followed by positive 90-day returns (+122.8%, +34.5%), while 2 saw declines (-77.4%, -46.7%), suggesting inconsistent timing at MRAI. The company remains unprofitable with a net loss of $3,560,000 in the latest quarter against $7,008,000 in quarterly revenue, though full-year revenue growth reached +52.6% year-over-year. The concurrent multi-insider buying activity warrants attention to whether this reflects information known to management or simply a reaction to the steep recent recovery.

President and COO John Paul Powers bought 10,000 shares of MRAI at $1.13 on 2024-12-05; cluster pattern with 2 other insiders buying in past 14 days

Powers, serving as President and COO, purchased 10,000 shares at $1.13 on 2024-12-05, increasing his holdings to 260,000 shares. This transaction is part of a broader insider accumulation pattern: 2 other insiders also bought within the past 14 days, forming a cluster buy. The timing occurs as the stock has rebounded significantly—up 63.1% over 30 days and 112.4% over 90 days—yet remains 54.8% below its 52-week high. Fundamentally, Marpai reported quarterly revenue of $7.0M with net income of -$3.6M, and the company was unprofitable over its most recent full fiscal year, though annual revenue growth reached 52.6%. The synchronized buying by multiple insiders at a point of substantial recent momentum in an unprofitable company with strong revenue growth warrants attention to whether management's buying reflects confidence in the business trajectory or other considerations.

MRAI CFO Johnson buys 5,000 shares at $1.13; stock +63.1% in 30d but -54.8% from 52-week high. Unprofitable fundamentals.

CFO Steve Andrew Johnson purchased 5,000 shares of Marpai at $1.13 on 2024-12-05, increasing his holdings to 473,061 shares. The purchase occurs within a broader cluster of 2 other insider buys in the past 14 days. While the stock has appreciated 63.1% over the past 30 days and 112.4% over 90 days from lower levels, it remains -54.8% from its 52-week high of $2.81, suggesting prior concentration of trading at much higher valuations. Johnson's own prior MRAI purchases (May 24 and May 29, 2024) produced 90-day returns of -61.9% and -26.2%, indicating a pattern of unfavorable timing at this ticker. The company's fundamentals show revenue of $7.0M with net income of -$3.6M in the latest quarter and negative full-year net income, creating tension between the recent stock momentum and underlying operational losses. The cluster buy pattern and recent price recovery warrant monitoring given the historical timing mismatch between insider acquisitions at this ticker and subsequent performance.